Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: Therapeutic approaches

BioEssays

Volumn 30, Issue 11-12, 2008, Pages 1172-1184

  Paul, Subhankar ^a  

^a NATIONAL INSTITUTE OF TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACLACINOMYCIN; ALPHA 1 ANTITRYPSIN; AMYLOID BETA PROTEIN; ARSENIC TRIOXIDE; ASCORBIC ACID; ATAXIN 1; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CARBOPLATIN; CELL PROTEIN; CEP 1612; COPPER ZINC SUPEROXIDE DISMUTASE; CVT 634; EPOXOMICIN; GEMCITABINE; HUNTINGTIN; LACTACYSTIN; LACTACYSTIN BETA LACTONE; MG 115; P 131; PARKIN; POLYGLUTAMINE; PRION PROTEIN; PROTEASOME; PROTEINASE INHIBITOR; SALINOSPORAMIDE A; TRANSMEMBRANE CONDUCTANCE REGULATOR; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG; BETA CATENIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHMA; CLINICAL TRIAL; CYSTIC FIBROSIS; DEGENERATIVE DISEASE; DRUG TARGETING; GENE FUNCTION; GENETIC DISORDER; HAPPY PUPPET SYNDROME; HUMAN; HUNTINGTON CHOREA; INFLAMMATORY DISEASE; LIDDLE SYNDROME; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRION DISEASE; PROTEIN DEGRADATION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DRUG ANTAGONISM; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; NEOPLASM; PHYSIOLOGY; PROTEIN DENATURATION; PROTEIN FOLDING;

ANIMALS; BETA CATENIN; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEURODEGENERATIVE DISEASES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN DENATURATION; PROTEIN FOLDING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UBIQUITIN;

EID: 58149159907     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.20852     Document Type: Review

References (110)

1. Reinstein E, Ciechanover A. 2006. Narrative review: protein degradation and human diseases. The ubiquitin connection. Annals Int Med 145:676-684.
2. Bader N, Jung T, Grune T. 2007. The proteasome and its role in nuclear protein maintenance. Exp Gerontol in press.
3. Heinemeyer W, Gruhler A, Mohrle V, Mahe Y, Wolf DH. 1993. PRE2, highly homologous to the human major histocompatibility complex-linked RING10 gene, codes for a yeast proteasome subunit necessary for chymotryptic activity and degradation of ubiquitinated proteins. J Biol Chem 268:5115-5120.
4. Ciechanover A. 2006. The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology 66:S7-19.
5. Malik B, Price SR, Mitch WE, Yue Q, Eaton DC. 2006. Regulation of epithelial sodium channels by the ubiquitin-proteasome proteolytic pathway. Am J Physiol Renal Physiol 290:F1285-1294.
6. Nalepa G, Rolfe M, Harper JW. 2006. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 5:596-613.
7. Dahlmann B. 2007. Role of proteasomes in disease. BMC Biochem 8: S3. Review.
8. Hideshima T, Bradner JE, Chauhan D, Anderson KC. 2005. Intracellular protein degradation and its therapeutic implications. Clin Cancer Res 11:8530-8533.
9. Lecker SH, Goldberg AL, Mitch WE. 2006. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 17:1807-1819.
10. Ciechanover A. 2003. The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting. Biochem Soc Trans 31:474-481.
11. Bross P, Corydon TJ, Andresen BS, Jorgensen MM, Bolund L, Gregersen N. 1999. Protein misfolding and degradation in genetic diseases. Human Mut 14:186-198.
12. Fink AL. 1999. Chaperone-mediated protein folding. Physiol Rev 79:425-449.
13. Hartl FU, Hayer-Hartl M. 2002. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295:1852-1858.
14. Carvalho P, Goder V, Rapoport TA. 2006. Distinct ubiquitin-ligase complexes define convergent pathways for the degradation of ER proteins. Cell 126:361-373.
15. Meusser B, Hirsch C, Jarosch E, Sommer T. 2005. ERAD: the long road to destruction. Nat Cell Biol 7:766-772.
16. Tsai B, Ye Y, Rapoport TA. 2002. Retro-translocation of proteins from the endoplasmic reticulum into the cytosol. Nat Rev Mol Cell Biol 3:246-255.
17. Hohfeld J, Cyr DM, Patterson C. 2001. From the cradle to the grave: molecular chaperones that may choose between folding and degradation. EMBO Rep 2:885-890.
18. Welchman RL, Gordon C, Mayer RJ. 2005. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol 6:599-609.
19. Hershko A, Ciechanover A. 1998. The ubiquitin system. Annu Rev Biochem 67:425-479.
20. Pickart CM, Eddins MJ. 2004. Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta 1695:55-72.
21. Glickman MH, Ciechanover A. 2002. The ubiquitinproteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373-428.
22. Price DL, Sisodia SS. 1998. Function and dysfunction of the presenilins. Annu Rev Neurosci 21:479-505.
23. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, et al. 1998. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature (London) 391:387-390.
24. Kim T-W, Pettingell WH, Hallmark OG, Moir RD, Wasco W, Tanzi RE. 1997. Endoproteolytic cleavage and proteasomal degradation of presenilin 2 in transfected cells. J Biol Chem 272:11006-11010.
25. Steiner H, Capell A, Pesold B, Citron M, Kloetzel PM, et al. 1998. Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation. J Biol Chem 273:32322-32331.
26. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Titani K, Ihara Y. 1993. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 10:1151-1160.
27. Lowe J, Mayer RJ, Landon M. 1993. Ubiquitin in neurodegenerative diseases. Brain Pathol 3:55-65.
28. van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, et al. 1998a. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 279:242-247.
29. van Leeuwen FW, Burbach JP, Hol EM. 1998b. Trends Neurosci 21: 331-335.
30. Hattori N, Mizuno Y. 2004. Pathogenetic mechanisms of parkin in Parkinson's disease. Lancet 364:722-724.
31. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
32. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr. 2002. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degrada-tion and Parkinson's disease susceptibility. Cell 111:209-218.
33. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, et al. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608.
34. Lücking CB, Dürr A, Bonifati V, Vaughan J, De Michele G, et al. 2000. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 342:1560-1567.
35. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, et al. 2003. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256-259.
36. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, et al. 2004. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304:1158-1160.
37. Ghee M, et al. 2000. Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. J Neurochem 75:2221-2224.
38. Lam YA, et al. 2002. A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal. Nature 416:763-767.
39. Hasegawa M, et al. 2002. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem 277:49071-49076.
40. Petrucelli L, et al. 2002. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36:1007-1019.
41. Miller DW, et al. 2003. L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J Biol Chem 278:36588-36595.
42. Moore DJ, et al. 2003. Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses. Neuromolecular Med 4:95-108.
43. Chung KK, et al. 2001. Parkin ubiquitinates the alpha-synuclein interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 7:1144-1150.
44. Wakabayashi K, et al. 2000. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol 47:521-523.
45. Landles C, Bates GP. 2004. EMBO Rep 10:958-963.
46. Paul S. 2007. Polyglutamine Mediated Neurodegeneration: Use of Chaperones as Prevention Strategy. Biochemistry (Moscow) 72:359-366.
47. Lieberman AP, Fischbeck KH. 2000. Triplet repeat expansion in neuromuscular disease. Muscle Nerve 23:843-850.
48. Ross CA. 2002. Polyglutamine pathogenesis: Emergence of unifying mechanisms for Huntington's disease and related disorders, Neuron 35:819-822.
49. La Spada AR, Taylor JP. 2003. Polyglutamines placed into context. Neuron 38:681-684.
50. Kalchman MA, Graham RK, Xia G, Koide HB, et al. 1996. Huntingtin is ubiquitinated and interacts with a specific ubiquitinconjugating enzyme. J Biol Chem 271:19385-19394.
51. Cummings CJ, Reinstein E, Sun Y, Antalffy B, Jiang Y, et al. 1999. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA mice. Neuron 4:879-892.
52. Prusiner SB. 2004. Prion biology and diseases. New York: Cold Spring Harbor Laboratory Press.
53. Kristiansen M, Deriziotis P, Dimcheff DE, et al. 2007. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell 26:175-188.
54. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, et al. 1993. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59-62.
55. Kishino T, Lalande M, Wagstaff J. 1997. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 15:70-73.
56. Laan LA, van Haeringen A, Brouwer OF. 1999. Angelman syndrome: A review of clinical and genetic aspects. Clin Neurol Neurosurg 101:161-170.
57. Albrecht U, Sutcliffe JS, Cattanach BM, Beechey CV, Armstrong D, et al. 1997. Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat Genet 17:75-78.
58. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, et al. 1994. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 79:407-414.
59. Staub O, Gautschi I, Ishikawa T, Breitschopf K, Ciechanover A, et al. 1997. Regulation of stability and function of the epithelial Na± channel (ENaC) by ubiquitination. EMBO J 16:6325-6336.
60. Kopito RR. 1999. Biosynthesis and degradation of CFTR. Physiol Rev 79:S167-S173.
61. Das SK, Ray K. 2006. Wilson's disease: an update. Nature Clinical Practice Neurology 2:482-493.
62. Colmegna I, Sainz B Jr, Garry RF, Espinoza LR. 2005. The proteasome and its implications in rheumatology. J Rheumatol 32:1192-1198.
63. Venuprasad K, Elly C, Gao M, et al. 2006. Convergence of Itch-induced ubiquitination with MEKK1-JNK signaling in Th2 tolerance and airway inflammation. J Clin Invest 116:1117-1126.
64. Lorrick KL, Jensen JP, Fang S, Ong M, Hatakayama S, Weissman AM. 1999. RING fingers mediate ubiquitin-conjugating enzyme (E2)- dependent ubiquitination. Proc Natl Acad Sci USA 96:11364-11369.
65. Chen A, Kleiman FE, Manley JL, Ouchi T, Pan ZQ. 2002. Autoubiquitination of the BRCA1-BARD1 RING ubiquitin ligase. J Biol Chem 277:22085-22092.
66. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, et al. 2001. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276:14537-14540.
67. Powell SM, Zilz N, Beazer-Barclay Y, et al. 1992. APC mutations occur early during colorectal tumorigenesis. Nature 359:235-237.
68. Munemitsu S, Albert I, Souza B, et al. 1995. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 92:3046-3050.
69. Werness BA, Levine AJ, Howley PM. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79.
70. Munger K, Werness BA, Dyson N, et al. 1989. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. Embo J 8:4099-4105.
71. Scheffner M, Huibregtse JM, Vierstra RD, et al. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
72. Li X, Coffino P. 1996. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 70:4509-4516.
73. Bubman D, Cesarman E. 2003. Pathogenesis of Kaposi's sarcoma. Hematol Oncol Clin North Am 17:717-745.
74. Benichou S, Benmerah A. 2003. The HIV nef and the Kaposi-sarcoma-associated virus K3/K5 proteins: "parasites" of the endocytosis pathway]. Med Sci (Paris) 19:100-106.
75. Coscoy L, Sanchez DJ, Ganem D. 2001. A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. J Cell Biol 155:1265-1273.
76. Sanchez DJ, Coscoy L, Ganem D. 2002. Functional organization of MIR2, a novel viral regulator of selective endocytosis. J Biol Chem 277:6124-6130.
77. Hewitt EW, Duncan L, Mufti D, Baker J, Stevenson PG, Lehner PJ. 2002. Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation. Embo J 21:2418-2429.
78. Yu Y, Wang SE, Hayward GS. 2005. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity 22:59-70.
79. Corn PG. 2007. Role of the ubiquitin proteasome system in renal cell carcinoma. BMC Biochem 8: S4.
80. Lopes UG, Erhardt P, Yao R, Cooper GM. 1997. P53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272: 12893-12896.
81. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, et al. 2001. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS- 341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61:3535-3540.
82. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. 2006. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57:33-47.
83. Gaczynska M, Osmulski PA. 2005. Small-molecule inhibitors of proteasome activity. Methods Mol Biol 301:3-22.
84. Tsukamoto S, Yokosawa H. 2006. Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development. Curr Med Chem 13:745-754.
85. Kisselev AF, Callard A, Goldberg AL. 2006. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 281:8582-8590.
86. Nawrocki ST, Carew JS, Pino MS, et al. 2005. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65:11658-11666.
87. Papandreou CN, Logothetis CJ. 2004. Bortezomib as a potential treatment for prostate cancer. Cancer Res 64:5036-5043.
88. Adams J. 2004. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4:349-360.
89. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, et al. 2002. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1:1243-1253.
90. Yang W, Monroe J, Zhang Y, George D, Bremer E, Li H. 2006. Proteasome inhibition induces both pro- and anti-cell death pathways in prostate cancer cells. Cancer Lett 243:217-227.
91. Thorpe JA, Christian PA, Schwarze SR. 2008. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis. Prostate 68:200-209.
92. 2-M-Phase Arrest and Apoptosis in Human Non-Small Cell Lung Cancer Cell Lines. Clin Cancer Res 9:1145-1154.
93. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H. 2004. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 95:176-180.
94. Bunn PA Jr. 2004. The Potential Role of Proteasome Inhibitors in the Treatment of Lung Cancer. Clinical Cancer Research 10:4263S-4265S.
95. Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, et al. 2008. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol 3: 68-74.
96. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, et al. 2001. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82:110-122.
97. Meiners S, Ludwig A, Stangl V, Stangl K. 2007. Proteasome inhibitors: Poisons and remedies. Med Res Rev Epub.
98. Chauhan D, Catley L, Li G, Podar K, Hideshima T, et al. 2005. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8:407-419.
99. Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS. 2007. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 13:1762-1768.
100. Stapnes C, Døskeland AP, Hatfield K, Ersvaer E, Ryningen A, et al. 2007. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 136:814-828.
101. Oikawa T, Sasaki T, Nakamura M, et al. 1998. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 246:243-248.
102. Hideshima T, Richardson P, Chauhan D, et al. 2001. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076.
103. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, et al. 2006. Effect of Bortezomib on Human Neuroblastoma Cell Growth, Apoptosis, and Angiogenesis. J Natl Cancer Inst 98:1142-1157.
104. Hamner JB, Dickson PV, Sims TL, Zhou J, Spence Y, et al. 2007. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma. Surgery 142:185-191.
105. Kim WY, Horbinski C, Sigurdson W, Higgins D. 2004. Proteasome inhibitors suppres formation of polyglutamine-induced nuclear inclusions in cultured postmitotic neurons. J Neurochem 91:1044-1056.
106. Inden M, Kondo JI, Kitamura Y, Takata K, Nishimura K, Taniguchi T, et al. 2005. Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats. J Pharmacol Sci 97:203-211.
107. Marambaud P, Ancolio K, Lopez-Perez E, Checler F. 1998. Proteasome inhibitors prevent the degradation of familial Alzheimer's disease-linked presenilin 1 and potentiate A beta 42 recovery from human cells. Mol Med 14:147-157.
108. Kienlen-Campard P, Feyt C, Huysseune S, de Diesbach P, N'Kuli F, Courtoy PJ, Octave JN. 2006. Lactacystin decreases amyloid-beta peptide production by inhibiting beta-secretase activity. J Neurosci Res 84:1311-1322.
109. Schwartz O, Maréchal V, Friguet B, et al. 1998. Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J Virol 72:3845-3850.
110. Elliott PJ, Pien CS, McCormack TA, et al. 1999. Proteasome inhibition: a novel mechanism to combat asthma. J Allergy Clin Immunol 104:1-7.